TY -的T1的bronchoprotective影响学龄前儿童吸入氟替卡松加沙美特罗:dose-ranging研究摩根富林明-欧洲呼吸杂志》乔和J SP - 78 LP - 81欧元六世- 13 - 1 AU Primhak RA AU -史密斯,CM AU - Yong, SC AU -瓦希,R AU -库里,米非盟-布朗,J R AU - Efthimiou Y1 - 1999/01/01 UR - //www.qdcxjkg.com/content/13/1/78.abstract N2 -婴儿和学龄前儿童的最佳剂量的氟替卡松加沙美特罗尚不清楚。本研究的目的是评估不同剂量沙美特罗对4岁以下儿童的支气管保护作用。有反复喘息病史的4岁儿童在7天内接受了两次乙酰胆碱挑战。在每次挑战前1小时，采用双盲方式使用计量吸入器和Babyhaler间隔器进行预处理。在一次挑战前给予安慰剂，在另一次挑战前给予25、50或100微克沙美特罗。剂量和治疗顺序都是随机的。每次都测量引起喘息(PCwheeze)的乙酰胆碱刺激浓度。当出现喘息或动脉氧饱和度(Sa,o2)低于91%时终止研究。在入选的42名儿童中，33人完成了研究。两名受试者拒绝挑战测试，两名受试者未能返回，五名受试者在两项测试之间出现上呼吸道感染或喘息。 The mean (range) age of the population was 27 (8-46) months. Ratios of PCwheeze between treatment and placebo challenges were calculated for each dosage group. The treatment/placebo ratios (95% confidence intervals) were 1.2 (0.6-2.4) for 25 microg, 2.5 (1.4-4.6) for 50 microg (p<0.01), and 4.0 (2.1-7.4) (p<0.001) for 100 microg doses. In recurrently wheezy children aged <4 yrs a single dose of salmeterol between 25 and 100 microg has a dose-dependent effect on methacholine-induced wheeze, and this is significantly different from placebo at 50 and 100 microg. This study suggests that the Babyhaler effectively delivers salmeterol to children <4 yrs of age and that doses between 50-100 microg are efficacious. ER -